Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTECT-2 induction study of ABX464 (obefazimod) in moderately to severely active ulcerative colitis
jRCT2031230081Phase 3Completed
- Sponsor
- Abivax
- Start
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing ABX464 arm with Placebo arm (2 arms). Primary endpoint: Clinical remission at week 8 (Modified Mayo Score). Started May 2023; status: completed.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031230081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230081.